Drug Profile


Alternative Names: 742457; GSK 742457; RVT-101; SB-742457

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Axovant Sciences; GlaxoSmithKline
  • Class Antidementias; Nootropics
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Dementia; Lewy body disease

Most Recent Events

  • 26 Sep 2017 Efficacy data indicating primary endpoint was not met from the phase III MINDSET trial in Alzheimer's disease (Adjunctive treatment) released by Axovant Sciences
  • 01 Sep 2017 Axovant Sciences completes the phase III MINDSET trial in Alzheimer's disease (Adjunctive treatment) in USA, European Union, Argentina, Australia, Canada, Chile, South Korea, Singapore, Serbia and Taiwan (PO) (NCT02585934)
  • 19 Jul 2017 Pharmacodynamic results from a preclinical study in Alzheimer's disease released by Axovant Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top